Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.56 |
| ▸ | ATR | Q13535 | 4/20 | 0.50 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488299 | 1.00 | MET (0.56) | METATRSMYD2CHEK2MAP4K4 | |
| SCHEMBL30453330 | 0.96 | MET (0.62) | METATRSMYD2CHEK2MAP4K4 | |
| SCHEMBL488485 | 0.96 | MET (0.62) | METATRSMYD2CHEK2MAP4K4 | |
| SCHEMBL30453089 | 0.96 | MET (0.61) | METATRCHEK2MAP4K4MAP4K3 | |
| SCHEMBL488531 | 0.96 | MET (0.61) | METATRCHEK2MAP4K4MAP4K3 | |
| SCHEMBL30452643 | 0.92 | MET (0.62) | METATRCHEK2MAP4K3MAPT | |
| SCHEMBL488473 | 0.92 | MET (0.62) | METATRCHEK2MAP4K3MAPT | |
| SCHEMBL30453345 | 0.91 | MET (0.68) | METATRCHEK2MAP4K4MAP4K3 | |
| SCHEMBL488463 | 0.91 | MET (0.68) | METATRCHEK2MAP4K4MAP4K3 | |
| SCHEMBL488699 | 0.90 | MET (0.55) | METATRSMYD2CHEK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |